Everything Medicare beneficiaries need to know about GLP-1 coverage rules, the new $50/month bridge program starting in July, what’s covered now, and how to reduce costs today.
Medicare coverage of Ozempic, Mounjaro, Wegovy, and Zepbound is one of the most rapidly evolving areas in federal health policy. As of April 2026, the rules are nuanced but changing fast: these drugs are covered by Medicare Part D for Type 2 diabetes, cardiovascular disease, and sleep apnea — but not (yet) for weight loss alone. Federal law has prohibited Medicare Part D from covering weight-loss drugs since 2003. That is finally changing: CMS announced in December 2025 that eligible Medicare Part D beneficiaries will be able to access certain GLP-1 drugs for weight management starting July 1, 2026, at a $50/month copay through a new bridge program. More than 17.7 million Medicare beneficiaries (over 26%) have Type 2 diabetes and may already qualify for coverage today. This guide covers every current rule, every upcoming change, how to get help paying, and what to ask your doctor right now.
-
1
Is Mounjaro covered by Medicare for weight loss? Not currently for weight loss — covered for Type 2 diabetesAs of April 2026, Mounjaro (tirzepatide, made by Eli Lilly) is covered by most Medicare Part D plans when prescribed for Type 2 diabetes management — more than 90% of commercial and Part D plans cover it for that indication, according to an Eli Lilly spokesperson cited by AARP (February 2026). Mounjaro is NOT covered for weight loss alone under standard Part D. The key nuance: the same molecule tirzepatide is also sold as Zepbound — which is FDA-approved for weight management and for obstructive sleep apnea in adults with obesity. Medicare Part D may cover Zepbound for sleep apnea (not weight loss). Starting July 2026, the Medicare GLP-1 Bridge may cover Mounjaro/Zepbound for weight management at $50/month for eligible beneficiaries. Whether the indication on your prescription is diabetes or weight loss determines coverage — not the drug itself. Source: CMS.gov Medicare GLP-1 Bridge; Wellcare Apr 2026; AARP Feb 7 2026.
-
2
Does Medicare cover Mounjaro for sleep apnea? Yes — Zepbound (same drug) is covered for moderate-severe OSA with obesityIn December 2024, the FDA approved Zepbound (tirzepatide — the same active ingredient as Mounjaro) specifically for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Because OSA is a covered medical condition (not purely a weight-loss indication), Medicare Part D plans can cover Zepbound for this use — subject to the plan’s formulary, prior authorization requirements, and step therapy rules. This has become a meaningful pathway for Medicare beneficiaries who have both obesity and sleep apnea to access tirzepatide through Medicare. Mounjaro itself is not specifically approved for sleep apnea — but Zepbound (tirzepatide) is. The prescription must document the OSA diagnosis, not weight loss, to qualify. Always ask your doctor whether your sleep apnea diagnosis qualifies you for Zepbound coverage before assuming you cannot access tirzepatide through Medicare. Source: Wellcare Apr 2026; FDA.gov December 2024 approval; CMS.gov Medicare GLP-1 Bridge; TheBig65.com Apr 2026.
-
3
When will Medicare cover weight loss drugs? July 2026 — $50/month Bridge program; full coverage starts January 2027This is the most significant Medicare drug policy change in decades. CMS announced on December 23, 2025, the Medicare GLP-1 Bridge — a short-term demonstration program providing Medicare Part D beneficiaries with access to certain GLP-1 drugs for weight management starting July 1, 2026, at a $50/month copay. This bridge runs July–December 2026. It is administered through Humana using the LI NET infrastructure. Full coverage through the BALANCE Model in Medicare Part D begins January 2027. Note: the original proposed rule change (late 2024) that would have allowed standard Part D weight-loss coverage starting January 2026 was NOT finalized in the April 2025 final rule by the new administration. The bridge program announced in December 2025 is the first concrete path to weight-loss coverage. Coverage details including specific qualifying criteria and eligible drugs will be released by CMS in Spring 2026. Source: CMS.gov Medicare GLP-1 Bridge; CMS.gov BALANCE Model; AARP Feb 7 2026.
-
4
Does Medicare currently cover Ozempic? Yes — for Type 2 diabetes, cardiovascular risk, and kidney disease; NOT for weight lossYes — most Medicare Part D plans cover Ozempic (semaglutide, made by Novo Nordisk) for three FDA-approved indications: (1) Type 2 diabetes management; (2) reduction of major cardiovascular events (heart attack, stroke, death) in adults with Type 2 diabetes and established heart disease; and (3) reduction of kidney disease worsening and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease (FDA approved this third indication most recently). Coverage is NOT available for weight loss alone. The critical rule: the FDA-approved reason documented in the prescription determines whether Medicare will pay — not the drug itself. What you pay: with Part D coverage, you pay your plan’s deductible (up to $615 in 2026) plus coinsurance (typically 25%) until you hit the $2,100 annual out-of-pocket cap, then you pay nothing for the rest of the year. Source: Wellcare Apr 2026; Drugs.com Feb 11 2026; FDA.gov; AARP Feb 7 2026.
-
5
How to get Ozempic for $25 a month — is it possible on Medicare? No — the $25 savings card EXCLUDES Medicare beneficiaries by federal lawThe Novo Nordisk Ozempic Savings Card ($25/month for up to 48 months) explicitly excludes all government beneficiaries — Medicare, Medicaid, Medigap, VA, DoD, and TRICARE are all excluded by the program terms. This is not Novo Nordisk’s choice — federal anti-kickback statutes prohibit drug manufacturer coupons from being used to reduce Medicare beneficiaries’ cost-sharing. Medicare beneficiaries have three pathways to reduce Ozempic costs: (1) Standard Part D coverage (if prescribed for diabetes, cardiovascular disease, or kidney disease) — 2023 ASPE data found median OOP for Ozempic under Medicare Part D was $15 or less per fill; (2) Extra Help / Low Income Subsidy (LIS) — reduces drug costs significantly for qualifying low-income beneficiaries; (3) Novo Nordisk Patient Assistance Program (PAP) — available for uninsured Medicare beneficiaries with household income at or below 200% FPL and those denied Extra Help; call 1-866-310-7549. Source: ozempic.com/savings; drugs.com Feb 23 2026; ASPE/HHS; novocare.com.
-
6
Does Medicare cover any weight loss programs? Yes — three programs available now under Part B, independent of drug coverageMedicare currently covers three weight management services under Part B that do not depend on drug coverage: (1) Intensive Behavioral Therapy (IBT) for Obesity — covered when you have a BMI of 30 or more and receive counseling from a primary care practitioner in a primary care setting. The Part B coinsurance and deductible are waived for this service. (2) Medical Nutrition Therapy (MNT) — covered under Part B if you have diabetes or kidney disease and are referred by your doctor. (3) Bariatric surgery — covered for certain conditions when specific medical criteria are met; discuss with your care team whether you qualify. These services are available now under original Medicare, regardless of which Part D plan you have and regardless of the drug coverage changes coming in July 2026. Source: Wellcare Apr 2026; CMS.gov Medicare coverage guidelines; Medicare.gov.
-
7
What organ is Ozempic hard on? Kidneys — dehydration from GI side effects; also watch thyroid and gallbladderThe most clinically important organ concern with Ozempic for seniors: the kidneys. Ozempic frequently causes nausea, vomiting, and diarrhea — especially in the early weeks of treatment. These GI side effects cause fluid loss, which can lead to dehydration, and dehydration can cause acute kidney injury. The FDA and Ozempic’s official prescribing information state: “Tell your health care provider right away if you have nausea, vomiting, or diarrhea that does not go away.” Seniors are at higher risk for dehydration-related kidney injury because they have reduced kidney reserve and may not feel thirsty even when dehydrated. Other documented organ concerns: (1) Thyroid — a boxed warning (the FDA’s most serious warning) notes thyroid tumors including cancer appeared in animal studies; do not use Ozempic if you or a family member have had medullary thyroid carcinoma (MTC) or MEN 2. (2) Gallbladder — gallbladder problems including gallstones are documented. (3) Pancreas — use with caution if you have a history of pancreatitis. Source: FDA.gov Ozempic prescribing information; ozempic.com medication guide; MedFinder Apr 2026; Drugs.com GoodRx.
-
8
Does Medicare cover Ozempic for obesity? Not for obesity alone under standard Part D — Wegovy yes, for cardiovascular riskOzempic itself is not approved for obesity or weight management — it is approved for Type 2 diabetes and cardiovascular/kidney protection. Medicare does not cover Ozempic for obesity. Wegovy (the higher-dose semaglutide product made by Novo Nordisk, approved for weight management) can be covered by Medicare Part D when prescribed specifically to reduce cardiovascular risk in adults with established cardiovascular disease who are overweight or obese — but not for weight loss alone. Starting July 2026, the Medicare GLP-1 Bridge is expected to cover Wegovy (and possibly other GLP-1s) for weight management at $50/month for eligible beneficiaries. Zepbound (tirzepatide) can currently be covered for obstructive sleep apnea in adults with obesity. For obesity without another qualifying condition, standard Part D coverage is not available until July 2026 at the earliest. Source: CMS.gov GLP-1 Bridge; Wellcare Apr 2026; TheBig65.com Apr 2026; AARP Feb 7 2026.
-
9
Does Medicare cover Mounjaro for high cholesterol? No — high cholesterol alone is not a covered indication for MounjaroMounjaro is FDA-approved only for Type 2 diabetes management. High cholesterol (hyperlipidemia) is not an FDA-approved indication for Mounjaro, and Medicare Part D cannot cover drugs for non-FDA-approved indications. While GLP-1 medications including tirzepatide have demonstrated improvements in lipid profiles in clinical studies — reducing triglycerides and improving HDL/LDL ratios — these effects are considered secondary benefits of diabetes or weight management treatment, not standalone indications. Some doctors may prescribe Mounjaro off-label for high cholesterol, but Medicare will not cover it for that reason. If Mounjaro is prescribed for your Type 2 diabetes and it also improves your cholesterol as a secondary benefit, Medicare Part D would cover it under the diabetes indication. Source: FDA.gov Mounjaro prescribing information; Wellcare Apr 2026; CMS.gov.
-
10
Does Medicare cover Mounjaro for high blood pressure? Not as a standalone indication — BUT uncontrolled hypertension qualifies for the July 2026 bridgeMounjaro is not FDA-approved for hypertension as a standalone indication, and Medicare Part D cannot cover it for that reason alone. However, the upcoming GENEROUS model (announced November 2025 by the Trump administration with Eli Lilly and Novo Nordisk) has specifically designated “uncontrolled high blood pressure” as a qualifying condition for Phase 2 of the GLP-1 coverage expansion. Phase 2 eligibility: overweight individuals with BMI greater than 30, plus uncontrolled hypertension, kidney disease, or heart failure. This means Medicare beneficiaries with obesity and uncontrolled high blood pressure would qualify for GLP-1 coverage under the phased program — but not under current standard Part D rules. If you have both obesity and high blood pressure, speak with your doctor about whether you qualify for the bridge program starting July 2026. Source: Ritter Insurance Marketing Nov 2025 (GENEROUS model phases); CMS.gov BALANCE; AARP Feb 7 2026.
Sources: CMS.gov Medicare GLP-1 Bridge cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge (July 1–Dec 31 2026; $50/month copay; announced Dec 23 2025; Humana LI NET administrator; Spring 2026 design details; [email protected]); CMS.gov BALANCE Model (Medicaid May 2026 opt-in; Medicare Part D Jan 2027; Dec 23 2025 announcement; lifestyle support program); AARP aarp.org Feb 7 2026 (90%+ plans cover Mounjaro T2D Eli Lilly; federal law 2003 bans weight-loss coverage; CMS final rule Apr 2025 did NOT finalize weight-loss coverage; drug price negotiation Ozempic/Rybelsus/Wegovy Jan 2025; MFP $274/30-day eff Jan 1 2027; AARP research Dec 18 2025 ≤$100/mo 7 of 10 drugs; 50% OOP decline; Part D OOP cap $2,100; deductible $615); Wellcare wellcare.com Apr 2026 (covered: Mounjaro/Ozempic/Rybelsus/Victoza/Trulicity T2D; Wegovy cardiovascular only; Zepbound OSA only; IBT Part B BMI≥30 waived coinsurance; MNT Part B diabetes/kidney; bariatric surgery); FDA.gov (Ozempic: T2D cardiovascular CKD; Wegovy: weight management Mar 2024 CV risk; Zepbound: Dec 2024 OSA; Mounjaro: T2D); Drugs.com Feb 11 2026 Leigh Ann Anderson PharmD (most Part D plans cover Ozempic T2D; mid-2026–2027 changes; $199 introductory cash); Ozempic.com / NovoCare (Savings Card $25 commercially insured ONLY; government beneficiaries EXCLUDED; PAP 1-866-310-7549; Medicare Part D no longer PAP eligible); NovoCare novocare.com (PAP 2026: Medicare Part D excluded; uninsured ≤200% FPL; Extra Help required if below 150% FPL); Drugs.com coupon Feb 23 2026 (Medicare excluded $25 coupon; anti-kickback federal law); ASPE/HHS aspe.hhs.gov (17.7M Medicare T2D 26%+; OOP median $15 or less; $60 avg; Ozempic list $969 2024 +43%); Ritter Insurance Marketing Nov 2025 (GENEROUS model announced Nov 6 2025; Eli Lilly + Novo Nordisk; Phase 1 BMI>27 prediabetes CVD; Phase 2 BMI>30 uncontrolled HTN CKD HF; Phase 3 BMI>35; $350/mo Wegovy/Zepbound starting; $245/mo Ozempic/Mounjaro starting; 10% Medicare beneficiaries); TheBig65.com Apr 2026 (Zepbound OSA pathway tirzepatide; Bridge July 2026 $50/mo; MFP Ozempic/Rybelsus/Wegovy Jan 1 2027; standard Part D deductible $615; OOP cap $2,100); FDA.gov ozempic.com (kidney: dehydration nausea vomiting diarrhea → acute kidney injury; thyroid boxed warning MTC MEN 2; gallbladder; pancreatitis caution; diabetic retinopathy; GI side effects most common)
| Drug | Type 2 Diabetes | Cardiovascular | Sleep Apnea (OSA) | Weight Loss Only |
|---|---|---|---|---|
| Ozempic (semaglutide) | ✅ Covered (Part D) | ✅ Covered (T2D + CVD) | ❌ Not approved | ⏳ July 2026 Bridge |
| Mounjaro (tirzepatide) | ✅ Covered (Part D) | ❌ Not FDA-approved for this | ❌ Not approved | ⏳ July 2026 Bridge |
| Wegovy (semaglutide) | ❌ Not FDA-indicated | ✅ Covered (established CVD + obesity) | ❌ Not approved for OSA | ⏳ July 2026 Bridge |
| Zepbound (tirzepatide) | ❌ Not FDA-indicated | ❌ Not approved for this | ✅ Covered (OSA + obesity) | ⏳ July 2026 Bridge |
| Rybelsus (oral semaglutide) | ✅ Covered (Part D) | ❌ Not indicated | ❌ Not approved | ❌ Not covered |
| Wegovy pill (new) | ❌ Not indicated | ❌ Not indicated | ❌ Not indicated | ⏳ Possible mid-2026+ |
⚠️ Coverage depends on your specific plan’s formulary, prior authorization requirements, and step therapy rules. ✅ “Covered” means the drug class is eligible — your individual plan must list it. Always verify with your plan’s member services. ⏳ July 2026 Bridge details to be released by CMS in Spring 2026.
Sources: Wellcare Apr 2026; CMS.gov Medicare GLP-1 Bridge; FDA.gov drug approvals; AARP Feb 7 2026; TheBig65.com Apr 2026
Sources: AARP aarp.org Feb 7 2026 (OOP cap $2,100; deductible $615; negotiated $274; 50% OOP decline); CMS.gov Medicare GLP-1 Bridge ($50/mo; no deductible; Humana LI NET); ASPE/HHS (17.7M T2D 26%+; $60 avg $15 median OOP); AARP Dec 18 2025 research (≤$100/mo 7 of 10 drugs; 50% decline 2025 vs 2026)
Sources: CMS.gov Medicare GLP-1 Bridge Dec 23 2025 (July 1–Dec 31 2026; $50/mo; no deductible; Humana LI NET; Spring 2026 details; [email protected]); CMS.gov BALANCE Dec 23 2025 (Jan 2027 Part D; May 2026 Medicaid; Dec 2031 end; lifestyle program no cost; [email protected]); Ritter Insurance Marketing Nov 2025 (GENEROUS Nov 6 2025; Eli Lilly + Novo Nordisk; phases 1–3; $350/$245 starting costs declining; 10% Medicare beneficiaries); Wellcare Apr 2026 (covered indications; prior auth step therapy; IBT Part B BMI≥30; MNT Part B; bariatric); FDA.gov (Ozempic T2D CVD CKD; Wegovy CV Mar 2024; Zepbound OSA Dec 2024; thyroid boxed warning); AARP Feb 7 2026 (90%+ plans Mounjaro T2D; federal law 2003 ban; negotiated $274; M3P option; HSA tax-free); TheBig65.com Apr 2026 (Zepbound OSA pathway; Bridge July 2026 $50; MFP Jan 2027); ozempic.com/NovoCare (1-866-310-7549; PAP 2026 changes; Medicare Part D excluded from PAP; ≤200% FPL uninsured; savings card commercially insured only); ASPE/HHS ($60 avg $15 median OOP; 17.7M T2D); SSA.gov Extra Help 1-800-772-1213
Yes — but only for specific, FDA-approved indications, not for weight loss. Most Medicare Part D plans cover Ozempic (semaglutide) when prescribed for: (1) Type 2 diabetes blood sugar management; (2) Cardiovascular risk reduction in adults with Type 2 diabetes and established heart disease; or (3) Kidney disease protection in adults with Type 2 diabetes and chronic kidney disease. If you have any of these diagnoses, your Part D plan likely covers Ozempic, though prior authorization and step therapy requirements may apply. What you’ll pay in 2026: your plan’s deductible (up to $615), then typically 25% coinsurance until you reach the $2,100 annual out-of-pocket cap. ASPE/HHS federal data from 2023 shows the median out-of-pocket cost for Medicare Part D Ozempic prescriptions was $15 or less per fill for most beneficiaries — because most people qualifying for these drugs have significant coverage through their plans. What Ozempic is NOT covered for: weight loss alone. That changes starting July 1, 2026, when the Medicare GLP-1 Bridge offers $50/month access for eligible beneficiaries with obesity. Source: Wellcare Apr 2026; Drugs.com Feb 11 2026; ASPE/HHS; CMS.gov GLP-1 Bridge.
The $25/month Novo Nordisk Savings Card that appears in most advertisements is explicitly unavailable to Medicare beneficiaries. Federal law (anti-kickback statute) prohibits drug manufacturer copay coupons from applying to government-insured patients. Medicare beneficiaries are specifically listed as excluded on the Ozempic savings card terms. Here are the legitimate cost-reduction options that DO work for Medicare beneficiaries: (1) Extra Help / LIS — if your income is below approximately 150% of the federal poverty level, apply for Extra Help at SSA.gov or call 1-800-772-1213. This program significantly reduces Part D drug costs including Ozempic. (2) Novo Nordisk Patient Assistance Program (PAP) — for uninsured Medicare beneficiaries with income at or below 200% of the Federal Poverty Level (~$31,300 single) who are not enrolled in Part D Extra Help; call 1-866-310-7549 or visit novocare.com. Note: Medicare Part D plan beneficiaries are no longer eligible for the PAP starting 2026, because 98% have access through their plans. (3) Medicare Prescription Payment Plan (M3P) — spreads your Part D drug costs evenly across 12 months rather than paying the full deductible and coinsurance upfront early in the year. (4) HSA funds — existing Health Savings Account balances can be withdrawn tax-free to pay for GLP-1s even if not covered by your plan, as long as a doctor prescribed them for a medical condition. Source: ozempic.com savings terms; drugs.com Feb 23 2026; novocare.com 2026; AARP Feb 7 2026.
This is finally happening — here is the confirmed timeline as of April 2026: July 1, 2026: The Medicare GLP-1 Bridge program begins. Eligible Medicare Part D beneficiaries can access certain GLP-1 drugs specifically for weight management at a $50/month copay with no deductible. CMS will release eligibility criteria and covered drugs in Spring 2026. January 2027: The BALANCE Model begins full Medicare Part D coverage of GLP-1s for weight management. January 2027: Medicare-negotiated prices for Ozempic, Rybelsus, and Wegovy ($274/30-day supply) take effect. What happened to the earlier proposal: CMS proposed a rule in late 2024 that would have allowed standard Part D weight-loss coverage starting in plan year 2026. When the final rule was published in April 2025 by the new administration, that provision was NOT included. The GENEROUS program announced in November 2025 and the Bridge program announced in December 2025 are the resulting alternative pathways. Key caveat: the bridge requires meeting qualifying criteria that CMS has not yet finalized. Coverage is not guaranteed for every Medicare beneficiary with obesity — specific income, BMI, and health condition criteria will apply. Source: CMS.gov GLP-1 Bridge; CMS.gov BALANCE; AARP Feb 7 2026; TheBig65.com Apr 2026.
For seniors, the organ requiring the most vigilance is the kidneys. GLP-1 drugs including Ozempic, Mounjaro, Wegovy, and Zepbound frequently cause nausea, vomiting, and diarrhea — especially in the first 4–8 weeks of treatment. These GI symptoms cause fluid loss, which can lead to dehydration, and dehydration is the most common trigger for acute kidney injury in seniors because older kidneys have reduced reserve capacity. The official Ozempic prescribing information states: “Tell your health care provider right away if you have nausea, vomiting, or diarrhea that does not go away.” The practical steps for seniors: drink small amounts of fluid frequently throughout the day from the first day on any GLP-1; do not wait until you feel thirsty; reduce doses of diuretic medications (“water pills”) only under your doctor’s direction if GI side effects are significant. Beyond the kidneys: the thyroid boxed warning (FDA’s most serious warning) applies to the entire GLP-1 class — if you or a family member have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), do not take these drugs. Additionally, gallbladder problems including gallstones are documented across the class. If you develop right-side abdominal pain, especially after eating fatty meals, report it to your doctor. Report all side effects to FDA at fda.gov/medwatch or 1-800-FDA-1088. Source: FDA.gov Ozempic prescribing information; ozempic.com medication guide; MedFinder Apr 2026.
Sources: CMS.gov Medicare GLP-1 Bridge (July 2026 $50/mo; Spring 2026 details); CMS.gov BALANCE Model (Jan 2027 Part D; May 2026 Medicaid); AARP aarp.org Feb 7 2026 (timeline; proposed rule not finalized Apr 2025; negotiated prices Jan 2027); Wellcare (current coverage; prior auth); Drugs.com Feb 11 2026 (Ozempic Part D coverage; $199 introductory cash); ozempic.com savings card (Medicare excluded; government beneficiaries excluded); novocare.com 2026 (PAP Medicare Part D no longer eligible; ≤200% FPL uninsured; 1-866-310-7549); Drugs.com Feb 23 2026 (coupon Medicare excluded anti-kickback); FDA.gov (kidney dehydration warning; thyroid boxed warning; gallbladder; prescribing info); MedFinder Apr 2026 (kidney seniors dehydration; gallbladder; pancreatitis caution); SSA.gov Extra Help 1-800-772-1213; TheBig65.com Apr 2026 (proposed rule not finalized; Bridge pathway; timeline)
- Step 1 — Check your current diagnoses with your doctor. Do you have Type 2 diabetes, established cardiovascular disease, obstructive sleep apnea, or chronic kidney disease? Any of these diagnoses may qualify you for GLP-1 coverage under your existing Part D plan today — without waiting for July 2026. Ask your doctor: “Based on my diagnosed conditions, is there a GLP-1 medication that Medicare currently covers for me?”
- Step 2 — Check your Part D plan’s formulary at Medicare.gov Plan Finder. Go to medicare.gov/plan-compare, log in, and search for Ozempic, Mounjaro, Wegovy, or Zepbound under your current plan’s drug list. This shows you whether the drug is covered, what tier it is on, and what prior authorization is required. Coverage varies significantly between plans — this is the only definitive way to know what your specific plan covers.
- Step 3 — If you have obesity AND another qualifying condition, ask your doctor about Wegovy or Zepbound now. Wegovy is coverable under Part D today for adults with established cardiovascular disease and obesity (since March 2024). Zepbound is coverable for moderate-to-severe obstructive sleep apnea with obesity (since December 2024). If you have sleep apnea and obesity or CVD and obesity, these are current pathways to access tirzepatide or semaglutide through Medicare without waiting.
- Step 4 — Apply for Extra Help / Low Income Subsidy if your income qualifies. If your household income is below approximately 150% of the Federal Poverty Level (~$22,590 for a single person in 2026), you may qualify for Extra Help (also called Low Income Subsidy or LIS), which significantly reduces Part D premiums, deductibles, and copays. Apply at SSA.gov or call 1-800-772-1213. Even if you’ve been denied before, eligibility changes annually.
- Step 5 — Watch for CMS eligibility details for the July 2026 bridge program. CMS will release the specific qualifying criteria, eligible drugs, and enrollment process for the Medicare GLP-1 Bridge in Spring 2026. The bridge begins July 1, 2026, at $50/month with no deductible. Stay informed by checking cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge for updates, or ask your pharmacist or Medicare counselor when the details are released.
This guide is independently researched for informational purposes only. We are not affiliated with, compensated by, or endorsed by CMS, Medicare, Novo Nordisk, Eli Lilly, Wellcare, or any plan mentioned. Medicare coverage rules, formularies, and program details change frequently and vary by plan. Always verify your specific plan’s coverage at medicare.gov/plan-compare or by calling your plan’s member services number. This content does not constitute medical, legal, or financial advice. All medication decisions must be made with and by your licensed healthcare provider. Ozempic® is a registered trademark of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company.
Primary sources: CMS.gov Medicare GLP-1 Bridge cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge (announced Dec 23 2025; July 1–Dec 31 2026; $50/mo copay no deductible; Humana LI NET administrator; Spring 2026 design details; [email protected]); CMS.gov BALANCE Model cms.gov/priorities/innovation/innovation-models/balance (Medicaid May 2026 opt-in; Medicare Part D Jan 2027; Dec 2031 end; lifestyle support free; [email protected]); AARP aarp.org Feb 7 2026 (90%+ plans cover Mounjaro T2D Eli Lilly spokesperson; 2003 Part D law bans weight-loss coverage; CMS proposed rule Dec 2024 not finalized Apr 2025 final rule; drug price negotiation Ozempic/Rybelsus/Wegovy selected Jan 2025; MFP $274/30-day eff Jan 1 2027; AARP research Dec 18 2025 avg OOP ≤$100 7 of 10 drugs; 50% OOP decline 2025 vs 2026; Part D OOP cap $2,100 up from $2,000; deductible $615 up from $590; HSA option; TrumpRx.gov; Mercer 49% employer plans cover weight loss GLP-1 2025; KFF Deputy Director quote on off-label); Wellcare wellcare.com Apr 2026 (covered: Mounjaro/Ozempic/Rybelsus/Victoza/Trulicity T2D; Wegovy cardiovascular established CVD + overweight/obese; Zepbound OSA obesity; NOT covered weight loss; IBT Part B BMI≥30 waived coinsurance/deductible; MNT Part B diabetes/kidney; bariatric surgery criteria; prior auth step therapy quantity limits); FDA.gov (Ozempic T2D CVD CKD FDA approvals; Wegovy weight management 2021 + CV risk Mar 2024; Zepbound weight management + OSA Dec 2024; Mounjaro T2D; Rybelsus T2D; Wegovy pill FDA approved Dec 2025); Drugs.com drugs.com Feb 11 2026 Leigh Ann Anderson PharmD (most Part D plans cover Ozempic T2D CVD CKD; mid-2026–2027 changes AARP cite; $199 introductory cash Ozempic; cash $800–$1,100/mo); ozempic.com NovoCare (savings card $25 commercially insured ONLY; government beneficiaries EXCLUDED max savings $100/$200/$300; PAP 1-866-310-7549; PAP 2026 Medicare Part D no longer eligible 98% have access; uninsured ≤200% FPL; Extra Help LIS 150% FPL proof of denial required); novocare.com (PAP 2026 eligibility; $31,300 single $42,300 married ≤200% FPL; Medicare Part D excluded; apply online; M3P spreading costs); Drugs.com Feb 23 2026 (coupon $25 commercially insured; Medicare/Medicaid/Medigap/VA/DoD/TRICARE excluded; anti-kickback); 340B Price Guide Oct 2025 (PAP changes 2026; 98% Medicare access explanation; Medicare Part D excluded starting 2026); Ritter Insurance Marketing Nov 12 2025 (GENEROUS announced Nov 6 2025 Trump + Eli Lilly + Novo Nordisk; Wegovy/Zepbound $350/mo Ozempic/Mounjaro $245/mo starting costs decreasing 2yr; Phase 1 BMI>27 prediabetes CVD; Phase 2 BMI>30 uncontrolled HTN CKD HF; Phase 3 BMI>35; 10% Medicare beneficiaries; state Medicaid opt-in letter of intent); TheBig65.com thebig65.com Apr 2026 (Zepbound OSA tirzepatide current pathway; Bridge July 2026 $50/mo; MFP Ozempic/Rybelsus/Wegovy Jan 1 2027 $274; deductible $615; OOP cap $2,100; prior proposed rule not finalized); ASPE/HHS aspe.hhs.gov (17.7M Medicare T2D 26%+; 4.6M AFib 4.1M HF; Mounjaro list $974 2022 $1,069 2023; Ozempic list $676 2017 $969 2024 +43%; Medicare Part D median OOP $15 or less fill avg $60; 2023 claims data); MedFinder medfinder.com Apr 2026 (kidney dehydration seniors; thyroid boxed warning; gallbladder; pancreatitis; retinopathy; cash $800–$1,100/mo without insurance); SSA.gov Extra Help 1-800-772-1213; Medicare.gov 1-800-MEDICARE; FDA MedWatch fda.gov/medwatch 1-800-FDA-1088